Bafiertam FDA Approval History
Last updated by Judith Stewart, BPharm on Sep 17, 2020.
FDA Approved: Yes (First approved April 28, 2020)
Brand name: Bafiertam
Generic name: monomethyl fumarate
Dosage form: Delayed-Release Capsules
Company: Banner Life Sciences LLC
Treatment for: Multiple Sclerosis
Bafiertam (monomethyl fumarate) is a novel fumarate indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Bafiertam (monomethyl fumarate) is a bioequivalent alternative to Tecfidera (dimethyl fumarate). Dimethyl fumarate is considered to be a prodrug of monomethyl fumarate.
Development timeline for Bafiertam
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
